Non-small Cell Lung Cancer Patients
Conditions
Brief summary
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking. Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.
Interventions
PROCEDURE18F-FDG-PET scan
Sponsors
University of Aarhus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Lung Cancer patients with non-small cell histology and stage IV disease * candidate for erlotinib treatment as first/ second/ third line of treatment
Exclusion criteria
* pregnancy * severe dyspnoea
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-FDG-PET evaluation | Time to progression and latest april 2015 (up to 2 years) | Standardized Uptake Values (SUV) will be used as measurement of 18F-FDG uptake |
Countries
Denmark
Outcome results
None listed